Overview

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

Status:
Recruiting
Trial end date:
2024-01-15
Target enrollment:
Participant gender:
Summary
A phase 1, open-label, dose escalation and expansion study of PF-07062119 in patients with selected advanced or metastatic gastrointestinal tumors
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Bevacizumab